IRLAB Therapeutics has announced job cuts affecting about ten positions as part of a strategic focus on revenue-generating partnerships. These layoffs represent approximately 30% of the company's workforce and are necessary due to a challenging partnership landscape expected to persist until late 2026.
The Gothenburg-based company aims to streamline its operations, with the cuts anticipated to reduce its annual cost base by about SEK 8 million. IRLAB will redirect resources toward prioritizing drug candidates within its extensive Parkinson’s disease project portfolio to enhance their attractiveness for potential partnerships.
Going forward, IRLAB will focus on commercializing its portfolio through partnerships and licensing agreements, indicating a clear shift towards sustainable business practices.
